Skip to search formSkip to main contentSkip to account menu

labetuzumab

Known as: monoclonal antibody hMN-14, hMN-14, MAb hMN14 
A humanized monoclonal antibody that recognizes carcinoembryonic antigen.
National Institutes of Health

Related topics

Related topics

2 relations

Broader (1)

Antibodies, Monoclonal, Humanized
antigen binding

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2012
Highly Cited
2012
Phase II Trial of Anticarcinoembryonic Antigen Pretargeted Radioimmunotherapy in Progressive Metastatic Medullary Thyroid Carcinoma: Biomarker Response and Survival Improvement
The prognosis of medullary thyroid carcinoma (MTC) varies from long- to short-term survival based on such prognostic factors as… 
Highly Cited
2009
Highly Cited
2009
CEACAM5-Targeted Therapy of Human Colonic and Pancreatic Cancer Xenografts with Potent Labetuzumab-SN-38 Immunoconjugates
Purpose: To improve the efficacy and reduce the gastrointestinal toxicity of the cancer prodrug, CPT-11, we have developed… 
Highly Cited
2006
Highly Cited
2006
Targeting, toxicity, and efficacy of 2-step, pretargeted radioimmunotherapy using a chimeric bispecific antibody and 131I-labeled bivalent hapten in a phase I optimization clinical trial.
UNLABELLED Safety, targeting, and antitumor efficacy of pretargeted radioimmunotherapy using anti-carcinoembryonic antigen (CEA… 
Highly Cited
2004
Highly Cited
2004
Reagents and methods for PET using bispecific antibody pretargeting and 68Ga-radiolabeled bivalent hapten-peptide-chelate conjugates.
UNLABELLED The aim of this work was to develop reagents and methods potentially useful in PET, using (68)Ga in a 2-step… 
Highly Cited
2003
Highly Cited
2003
Pharmacokinetics and dosimetry studies for optimization of anti-carcinoembryonic antigen x anti-hapten bispecific antibody-mediated pretargeting of Iodine-131-labeled hapten in a phase I…
PURPOSE Pharmacokinetics and dosimetry of hMN-14 x m734 bispecific monoclonal antibody (BsMAb) and (131)I-labeled di… 
Highly Cited
2003
Highly Cited
2003
Optimizing bispecific antibody pretargeting for use in radioimmunotherapy.
PURPOSE With increasing interest in pretargeting procedures for improving the delivery of radionuclides for cancer imaging and… 
Highly Cited
2000
Highly Cited
2000
Experimental pretargeting studies of cancer with a humanized anti-CEA x murine anti-[In-DTPA] bispecific antibody construct and a (99m)Tc-/(188)Re-labeled peptide.
The aim of this study was to localize (99m)Tc and (188)Re radionuclides to tumors, using a bispecific antibody (bsMAb) in a two… 
Highly Cited
1999
Highly Cited
1999
Radioimmunotherapy of small volume disease of colorectal cancer metastatic to the liver: preclinical evaluation in comparison to standard chemotherapy and initial results of a phase I clinical study.
At the time of surgery, occult metastases (micrometastases) are present in more than 50% of colorectal cancer patients, and the… 
Highly Cited
1997
Highly Cited
1997
Variables influencing tumor dosimetry in radioimmunotherapy of CEA-expressing cancers with anti-CEA and antimucin monoclonal antibodies.
UNLABELLED In this study, we examined the factors that may influence tumor dosimetry in the radioimmunotherapy of solid, CEA… 
Highly Cited
1995
Highly Cited
1995
Evaluation of a complementarity-determining region-grafted (humanized) anti-carcinoembryonic antigen monoclonal antibody in preclinical and clinical studies.
A complementarity-determining region-grafted (humanized) version of MN-14 (hMN-14), a high-affinity, anti-carcinoembryonic… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)